Piper Sandler Reiterates Overweight on Xeris Biopharma Holdings, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Xeris Biopharma Holdings (NASDAQ:XERS), while lowering the price target from $4 to $3.

May 10, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Xeris Biopharma Holdings but reduced the price target from $4 to $3, indicating a positive outlook with a reduced valuation expectation.
The reiteration of an Overweight rating suggests a positive outlook on XERS by Piper Sandler, indicating confidence in the company's fundamentals or growth prospects. However, the reduction in the price target could reflect adjustments in valuation metrics, possibly due to market conditions or revised earnings expectations. This mixed signal might lead to short-term uncertainty among investors, balancing the potential for both positive and negative reactions in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100